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Abstract
Background: Hypoxic-ischaemic encephalopathy is associated with development of cerebral palsy and cognitive
disability later in life and is therefore one of the fundamental problems in perinatal medicine. The xanthine-oxidase
inhibitor allopurinol reduces the formation of free radicals, thereby limiting the amount of hypoxia-reperfusion
damage. In case of suspected intra-uterine hypoxia, both animal and human studies suggest that maternal
administration of allopurinol immediately prior to delivery reduces hypoxic-ischaemic encephalopathy.
Methods/Design: The proposed trial is a randomized double blind placebo controlled multicenter study in
pregnant women at term in whom the foetus is suspected of intra-uterine hypoxia.
Allopurinol 500 mg IV or placebo will be administered antenatally to the pregnant woman when foetal hypoxia is
suspected. Foetal distress is being diagnosed by the clinician as an abnormal or non-reassuring foetal heart rate
trace, preferably accompanied by either significant ST-wave abnormalities (as detected by the STAN-monitor) or an
abnormal foetal blood scalp sampling (pH < 7.20).
Primary outcome measures are the amount of S100B (a marker for brain tissue damage) and the severity of oxida-
tive stress (measured by isoprostane, neuroprostane, non protein bound iron and hypoxanthine), both measured in
umbilical cord blood. Secondary outcome measures are neonatal mortality, serious composite neonatal morbidity
and long-term neurological outcome. Furthermore pharmacokinetics and pharmacodynamics will be investigated.
We expect an inclusion of 220 patients (110 per group) to be feasible in an inclusion period of two years. Given a
suspected mean value of S100B of 1.05 ug/L (SD 0.37 ug/L) in the placebo group this trial has a power of 90%
(alpha 0.05) to detect a mean value of S100B of 0.89 ug/L (SD 0.37 ug/L) in the ‘allopurinol-treated’ group (z-test2-
sided). Analysis will be by intention to treat and it allows for one interim analysis.
Discussion: In this trial we aim to answer the question whether antenatal allopurinol administration reduces
hypoxic-ischaemic encephalopathy in neonates exposed to foetal hypoxia.
Trial registration number: Clinical Trials, protocol registration system: NCT00189007
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Hypoxic-ischaemic encephalopathy is associated with
development of cerebral palsy and cognitive disability
later in life [1]. The recognition, prevention and treat-
ment of intra-uterine hypoxia is therefore one of the
main priorities in perinatal medicine. Animal and
human studies have shown that brain damage not only
occurs during the hypoxic-ischaemic event, but con-
tinues for hours up to days upon and after reoxygena-
tion and reperfusion and is caused by production of free
radicals [2].
Free radical formation due to conversion of hypox-
anthine into xanthine by xanthine-oxidase is very impor-
tant during this process [3]. Administration of the
xanthine-oxidase inhibitor allopurinol (ALLO) reduces the
production of free radicals, thereby limiting the amount of
hypoxia-reperfusion damage [4,5]. Furthermore, ALLO
also has a non-protein bound iron (pro-radical) chelating
and direct free radical (hydroxyl) scavenging effect. Animal
research in asphyxiated pigs demonstrated beneficial
effects of postnatally administrated ALLO on cerebral
energy status and cytotoxic oedema [6].
A prospective randomized study in human neonates,
examining the effects of ALLO in term asphyxiated neo-
nates, showed an improvement of electrocortical brain
activity and a reduction in free radical formation after
neonatal ALLO administration [7]. A more recent paper
by Gunes et al [8] reports an improved neurological out-
come after postnatal ALLO administration compared to
a placebo in term asphyxiated neonates. Benders et al
h o w e v e rd e m o n s t r a t e dt h a tA L L Ow a sn o te f f e c t i v ei f
administrated 3 to 4 hours after the hypoxic incident to
severely asphyxiated neonates [9]. However, when the
most severely asphyxiated children were excluded from
the study, a beneficial effect of ALLO was seen on neuro-
logical development. This is in line with previous studies
by Gluckman et al on neonatal head cooling [10]. They
also demonstrated a beneficial effect of their treatment
after exclusion of the most severely asphyxiated neonates.
Apparently, no advantage of neonatal treatment is seen
anymore, when the interval to the initiation of treatment
is too long or when the brain damage is too severe. This
has probably been the major disadvantage of late post
neonatal treatment with ALLO on the Neonatal Intensive
Care Unit (NICU). ALLO administrated at the NICU is
likely to be given too late to provide adequate neuropro-
tection during the early period of reoxygenation in which
the vast amount of free radicals is being produced.
Apparently, when the asphyxia has been too severe,
the inflicted brain damage can no longer be reversed. It
is conceivable that earlier ALLO treatment, i.e. the use
of ALLO during labour in case of suspected foetal
hypoxia, provides the opportunity to start earlier with
the treatment, thereby limiting the amount of hypoxia-
reperfusion injury and improving neurological outcome.
Pharmacological data have been published by Boda et
al, who showed that pharmacological plasma levels were
reached in the human foetus after ALLO administration
to the mother [11]. A systematic review in Pubmed,
searching for [allopurinol, foetus, neonate, asphyxia,
hypoxia] did not provide us with any additional studies
performed in humans. Some animal studies have been
performed using piglets (neonatal administration), sheep
and sows (maternal administration) [6,12-14]. These stu-
dies showed improved outcome after allopurinol treat-
ment on cerebral energy status and recovery of
umbilical blood flow respectively.
We recently performed a prospective randomized pla-
cebo controlled pilot study, in which we administered
ALLO to the pregnant woman when foetal asphyxia was
imminent. Data from this pilot study show an inverse
correlation between levels of ALLO and the amount of
S100B, a biomarker for brain tissue damage, in cord
blood [15]. In addition, we performed a study in the
chronically instrumented foetal sheep, in which we
showed evidence of cardio- and neuroprotection after
antenatal ALLO administration to the pregnant ewe
during repeated periods of ischaemia [13,16].
Incidence and financial impact of birth asphyxia
Birth asphyxia carries a high incidence, 4-9 per 1000 live
born neonates. On estimate 1-4 of these neonates will
die or develop a severe handicap [17,18]. With almost
200.000 deliveries in the Netherlands annually, this
implicates that each year approximately 800 neonates
will die or suffer from a handicap due to birth asphyxia.
Moreover, there is evidence that individuals suffering
from moderate birth asphyxia, develop behavioural pro-
blems later in life [19].
The health care costs of asphyxia are enormous. Many
of these children are admitted to a neonatal intensive care
unit at a cost of € 1.500, - per day, with an average dura-
tion of admission of 10 days. Estimated costs of disabled
children are € 80.000, - and € 20.000, - yearly for severely
and moderately handicapped children respectively. The
costs of neonatal care are annually 20 million Euros,
whereas the costs of care for disabled children born in one
year are more than one hundred million Euros.
As the costs of ALLO and its administration are rela-
tively low (100 Euros per pregnant woman), a small
treatment effect will already make the intervention cost-
effective.
Safety of allopurinol
Allopurinol has been used in internal medicine for many
years for the treatment of gout. Side effects of ALLO are
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sensitivity like skin rashes [20]. Stevens-Johnson syn-
drome has been reported, but only after prolonged
treatment (> 10 days) in case of gout [21]. During pre-
viously performed studies in pregnant women and neo-
nates, no adverse reactions were seen [11,15,22,23].
Methods/Design
Aims
The objective of the study is to test the hypothesis that
intra-uterine treatment with ALLO in case of suspected
foetal hypoxia will reduce brain damage and with that
may improve neonatal outcome.
Participants/eligibility criteria
Pregnant women with a gestational age of at least 36
weeks and suspected intra-uterine hypoxia (foetal distress)
during labour can be included in the trial. Foetal distress
is being diagnosed by the clinician as an abnormal or non-
reassuring foetal heart rate trace, preferably accompanied
by either significant ST-wave abnormalities (as detected by
the STAN-monitor) or an abnormal foetal blood scalp
sampling (pH < 7.20). Neonates suspected of chromoso-
mal or congenital anomalies will be excluded.
Procedures, recruitment, randomization and collection of
baseline data
T h es t u d yw i l lb ear a n d o m i z e dd o u b l eb l i n dp l a c e b o
controlled multicenter study. Hospitals which participate
in the Dutch Consortium for Studies in Women’s health
and reproductivity will participate in the trial. The study
will be staffed by research midwives and -nurses, who
will counsel patients at the outpatient clinic or at the
obstetric ward.
Before entry into the study, subjects will be informed
about the aims, methods, reasonably anticipated benefits
and potential hazards of the study. Subjects will be
informed that their participation is voluntary and that they
may withdraw consent to participate at any time during
the study. They will be informed that choosing not to par-
ticipate will not affect their care. In every center an inde-
pendent gynaecologist will be available for more detailed
information both for patients and colleagues if required.
After giving sufficient information, written informed con-
sent will be obtained. The consent form must be signed
before performance of any study-related activity.
In case of suspected foetal distress and written
informed consent, the patient will be randomized imme-
diately prior to delivery (Figure 1).
All details of delivery are recorded in the case record
form that is accessible through a website http://www.
studies-obsgyn.nl/allo. In case of admittance of one or
more children to the neonatal intensive care unit, details
of this admittance are also recorded.
Data will be collected using Oracle Clinical Remote
Data Capture (RDC), which is a new generation of
application systems that enable collection and cleanup
of clinical trial data using the Internet. For detailed
information on Oracle RDC see http://www.ctc-g.co.jp/
~CTCLS/opa/en/. The expertise for this technology is
a l r e a d yu s e di nt h es t u d yg r o u pa n da p p l i e di nt h e
ZonMw funded consortium studies that are currently
running.
Interventions
All women who are identified as having suspected foetal
distress and have given informed consent prior to deliv-
ery will be randomized in two groups:
One group of pregnant women will receive one IV
dosage of 500 mg ALLO. The other group will receive
one IV dosage of placebo antenatally.
Outcome measures
Primary outcome measures are related to biochemical
brain damage markers (S100B, enolase) and the severity
of oxidative stress as measured by isoprostane, neuro-
prostane, non protein bound iron and hypoxanthine in
umbilical cord blood.
The main primary outcome measure will be the pro-
tein S100B as this is, at present, the most validated bio-
chemical marker for brain tissue damage.
Secondary outcome parameters are neonatal mortality
and short term neonatal morbidity, such as hypoglycae-
mia, convulsions and post-hypoxic neonatal encephalo-
pathy, length of admission at the neonatal intensive care
unit and placental transfer, pharmacodynamics and
-kinetics of ALLO. Neonatal encephalopathy will be
assessed by Sarnat- and Thompson scores [24,25].
Follow up of women and infants
Blood sampling will be performed to assess the amount
of tissue damage (i.e. S100B, enolase, troponin), oxida-
tive stress (i.e hypoxanthine, isoprostane, neuroprostane
and non protein bound iron) and ALLO plasma levels.
Immediately after delivery, samples of cord blood and
maternal blood are obtained. One hour and 18-24 hours
after birth neonatal blood samples are obtained in all
children with clinically indicated blood sampling.
Long-term follow-up using neuropsychological tests
and validated neurodevelopmental questionnaires at the
age of 4-5 and 8 years and additional MRI at the age of
8 years is desirable, but is depending on future funding.
Statistical issues
Sample size
The sample size is calculated based on the primary out-
come measure cord-S100B as a marker of brain damage.
Our own pilot study showed a mean value of S100B of
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Page 4 of 61.05 ug/L (SD 0.37 ug/L) in the ‘non-treated’ group with
suspected intra-uterine hypoxia. Based on this same
pilot study we expect the mean value of S100B to be
lower in the ‘allopurinol-treated’ group compared to the
‘non-treated group’.
Based on the accrual of patients in our pilot study we
consider an inclusion of 220 patients (110 ALLO, 110
placebo) to be feasible in an inclusion period of 2 years.
Given a suspected mean value of S100B of 1.05 ug/L
(SD 0.37 ug/L) in the placebo group this trial has a
power of 90% with an alpha of 0.05 to detect a mean
value of S100B of 0.89 ug/L (SD 0.37 ug/L) in the ‘allo-
purinol-treated’ group (z-test2-sided)[15].
Data analysis
Data will be analyzed according to the intention to treat
principle. Outcome measures will be analyzed with
(non)parametric tests where continuous variables are
concerned. Proportional data will be reported as relative
risks with 95% confidence intervals. Multivariable
regression techniques will be applied to correct for any
important differences in prognostic baseline characteris-
tics, despite of randomization, by adding all prognostic
variables as independent variables. Both corrected and
uncorrected group differences will be reported. Num-
bers needed to treat (NNT) will be reported for both
continuous and discrete data.
Interim analysis
An interim analysis will be performed at t = 0.5 using
O’Brien -Fleming alpha spending function. An interim
analysis will be performed after the inclusion of 110
women. This analysis will be done by an independent
person that will be unaware of the allocation of treat-
ment or placebo when they judge data on effectiveness.
Data safety monitoring committee
Serious Adverse Events (SAEs) and Suspected Unexpected
Serious Adverse Reactions (SUSARs) will be reported to a
Data Safety Monitoring Committee (DSMC). The DSMC
can order to perform an extra interim analysis and, if
indicated, terminate the trial prematurely.
Ethical considerations
This study is approved by the National Central Commit-
tee on Research involving Human Subjects (CCMO -
NL26516.000.09).
Discussion
In conclusion, hypoxic-ischaemic encephalopathy is
associated with development of cerebral palsy and cog-
nitive disability later in life and is therefore one of the
fundamental problems in perinatal medicine. Prevention
of brain damage and developing adequate therapy is
therefore of big importance. The xanthine-oxidase inhi-
bitor allopurinol (ALLO) reduces free radical formation,
thereby limiting the amount of hypoxia-reperfusion
damage. Animal and human studies suggest that admin-
istration of ALLO immediately prior to delivery in case
of suspected foetal asphyxia might reduce hypoxic-
ischaemic encephalopathy. We designed a randomized
placebo controlled multicenter trial to determine
whether intra-uterine treatment with allopurinol reduces
hypoxic-ischaemic encephalopathy in neonates exposed
to foetal hypoxia.
T oo u rk n o w l e d g en os i m i l a rs t u d i e sa r eo rw i l l
shortly be performed in the Netherlands or abroad.
Abbreviations
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